

*At  
conclude*

(d) examining the treated test cell to determine whether it exhibits a change in the phenotypic characteristic in response to the substance.

---


REMARKS

*FNS B1*

Claims 1 through 30 have been canceled, and new claims 31 and 32, directed to pharmaceutical compositions and substances, have been added. Favorable consideration and allowance of claims 31 and 32 is respectfully requested.

Respectfully submitted,  
KENYON & KENYON

Dated: February 22, 2000

By:   
M. Lisa Wilson  
Reg. No. 34,045

KENYON & KENYON  
One Broadway  
New York, NY 10004

Tel: 212-425-7200  
Fax: 212-425-5288  
Direct: 212-908-6366